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Abstract Objective: We aimed to assess cancer risk in congenital heart defect patients, with and without
Down’s syndrome, compared with the general population. Methods: We identified all patients born and
diagnosed with congenital heart defects from 1977 to 2008 using the Danish National Registry of Patients,
covering all Danish hospitals. We compared cancer incidence in the congenital heart defect cohort with that
expected in the general population (,5.5 million) using the Danish Cancer Registry, and computed age- and
gender-standardised incidence ratios. Results: We identified 15,905 congenital heart defect patients,
contributing a total of 151,172 person-years at risk; the maximum length of follow-up was 31 years
(median 8 years). In all, 53 patients were diagnosed with cancer, including 30 female and 23 male patients
(standardised incidence ratio5 1.63; 95% confidence interval: 1.22–2.13). Risks were increased for
leukaemia, brain tumours, and basal cell carcinoma. After excluding 801 patients with Down’s syndrome, the
standardised incidence ratio was 1.19 (95% confidence interval: 0.84–1.64). In the subgroup of 5660 non-
Down’s syndrome patients undergoing cardiac surgery or catheter-based interventions, the standardised
incidence ratio was 1.45 (95% confidence interval: 0.86–2.29). Conclusion: The overall risk of cancer among
congenital heart defect patients without Down’s syndrome was not statistically significantly elevated. Cancer
risk in the congenital heart defect cohort as a whole, including patients with Down’s syndrome, was increased
compared with the general population, although the absolute risk was low. Studies with longer follow-up and
more information on radiation doses are needed to further examine a potential cancer risk associated with
diagnostic radiation exposure.
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L
ONG-TERM SURVIVAL OF PATIENTS WITH CONGENITAL
heart defects has improved dramatically during
the recent decades,1,2 and many grown-ups with
congenital heart defects now live to face potential
long-term complications.3 Cancer risk is a concern
in the congenital heart defect population, owing
to the potential radiation exposure from cardiac
catheterisation.4 Furthermore, congenital heart defects
are associated with cancer-linked genetic factors such
as Noonan syndrome,5 Fanconi anaemia,6 and most
importantly Down’s syndrome.7
Before the introduction of echocardiography in
the 1980s, cardiac catheterisation was used to
examine most children with suspected haemodyna-
mically significant congenital heart defect, and
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today cardiac catheterisation is used primarily and
increasingly for therapeutic purposes.8 In addition
to the radiation from catheter-based procedures,
patients with congenital heart defects are often
exposed to radiation from chest X-ray and com-
puted tomography.9 A recent case–control study
indicates an association between radiation early in
life and increased risk of childhood cancer.10
Furthermore, studies have found increased levels
of biomarkers of DNA damage following paediatric
catheterisation, indicating an increased cancer risk.11
However, few studies exist on long-term cancer risk
following cardiac catheterisation,12,13 and their inter-
pretation is hampered by incomplete follow-up.
The complete follow-up for up to more than
30 years, in the Danish nationwide health-care regis-
tries, enables assessment of the long-term cancer
risk in congenital heart defect patients compared
with the risk in the general population. Owing to
the fact that detailed information on cardiac
catheterisation and radiation dosage is not available
in these registries, our ability for causal inference in
this regard is limited. Nevertheless, more knowledge
on cancer risk in the congenital heart defect
population, with and without Down’s syndrome,
will provide important additional prognostic insight.
Methods
The National Patient Registry was established in
1977, and 99.4% of all discharges from Danish
medical hospitals are recorded there. Recorded
information includes the civil registration number,
which is unique to every Danish citizen, the dates of
hospital admission and discharge, the surgical or
other therapeutic procedures performed, and up to
20 discharge diagnoses, classified according to the
International Classification of Diseases, 8th Revision
(ICD-8) before 1 January, 1994 and later version
10 (ICD-10). It is possible to obtain the full discharge
history of a patient by linking discharge records to the
civil registration number. All persons born from
1 January, 1977 to 31 December, 2008 and registered
in the National Patient Registry during the same
period with a congenital heart defect diagnosis
following hospitalisation or outpatient clinic visit
were included in the study. To minimise misclassifica-
tion of congenital heart defects, we excluded patients
with, for example, unspecific congenital heart defect
diagnoses (n5 2566), according to the current criteria
of the Danish Registry of Congenital Heart Disease.14
The criteria are based on record review and consensus-
based decisions of a board of paediatric cardiologists
and cardiac surgeons. Please see online Appendix for
specific International Classification of Diseases codes.
Using the National Patient Registry, we identified
patients with Down’s syndrome and also the less
prevalent Fanconi anaemia, both known to be
associated with congenital heart defect and haemato-
logical cancers.6,15 Detailed data on catheter-based
investigations and following radiation dosage were not
available. However, we were able to identify the
patients who underwent therapeutic cardiac interven-
tions. These patients were more likely exposed to
radiation during diagnostic examinations and clinical
follow-up than patients who did not undergo cardiac
interventions. Until 1987, all operated patients under-
went at least one heart catheterisation. From 1987,
some patent ductus arteriosus/Atrial septal defect/
ventricular septal defect/pulmonary stenosis patients
were operated on the basis of echocardiographic
examinations alone, but some were catheterised.
Catheter-based therapeutic cardiac interventions
were introduced in the early 1990s and also exposed
the patients to radiation.
All members of the study cohort were linked
through their civil registration numbers to the
Cancer Registry, which has kept records of all
incident cases of cancer in Denmark (population
,5.5 million) since 1943, including benign brain
tumours. Follow-up for cancer started on 1 January,
1978, because diagnoses in the Cancer Registry
have been converted to the International Classifica-
tion of Diseases version 10 from this date. The
inclusion of benign brain tumours is in accordance
with other cancer registries, and depending on
localisation benign and malignant brain tumours
may have similar symptoms and outcomes.16
Furthermore, benign brain tumours have been
associated with radiation in terms of, for example,
radiotherapy for tinea capitis – ringworm of the
scalp – 17 and computed tomography scans of
the brain.18 Cancers are classified according to the
International Classification of Diseases version 10
and diagnoses of pre-cancerous lesions were ignored
in the present study, including carcinoma in situ of
the breast, dysplasia of cervix uteri, and carcinoma
in situ of cervix (International Classification of
Diseases version 10 codes: D05, N87, D06, O01,
D39.2, D45.9, D46, D47.1, D47.3). The registra-
tion is based on notification forms that are filled in
by hospital departments, including departments of
pathology and forensic medicine, and practising
physicians. Registration takes place whenever a case
of cancer is diagnosed or found at autopsy and
whenever there are changes in an initial diagnosis.
The cases recorded manually are supplemented by
unreported cases revealed by computerised linkages
to the death certificate file and the National Patient
Registry. Ambiguous or contradictory information,
either within a notification form or between forms,
leads to queries in ,10% of the notifications
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received. Comprehensive evaluation has shown that
the Cancer Registry is 95–98% complete and valid.19
Statistical analyses
Each patient was followed up for the occurrence of
cancer from the date of the first hospitalisation or
outpatient clinic visit with congenital heart defect
until the date of death or 31 December, 2008,
whichever came first. In analyses restricted to
patients undergoing therapeutic procedures, fol-
low-up started on the date of the first procedure.
We excluded patients if a cancer was diagnosed
before the congenital heart defect. We used the
Civil Registration System to identify dates of death
or emigration, and used the national incidence rates
obtained from the Cancer Registry, combined with
the Civil Registration System, to compute the
expected number of cancers in the congenital heart
defect cohort according to sex, age, and calendar period
in 1-year intervals. We computed the standardised
incidence ratio as the ratio of observed to expected
cases. Analyses were repeated after exclusion of patients
with Down’s syndrome or Fanconi anaemia, and after
restriction to congenital heart defect patients under-
going therapeutic cardiac interventions, in terms of
surgery or catheter-based intervention. Analyses were
performed using SAS v.9.
Results
Characteristics
We identified 15,905 congenital heart defect
patients (Table 1), of whom 796 had associated
Down’s syndrome and five had Fanconi anaemia,
including 51% male patients. The median age at
congenital heart defect diagnosis was 4 months, and
6148 (39%) underwent one or more therapeutic
cardiac procedures at some point during follow-up.
Standardised incidence ratio of cancer
The overall standardised incidence ratio was 1.63
(95% confidence interval: 1.22–2.13), based on 53
observed and 32.6 expected cancers, after a total of
151,172 person-years at risk – 31 years maximum
follow-up and 8 years median follow-up (Table 2).
After exclusion of patients with Down’s syndrome,
the standardised incidence ratio was 1.19 (95%
confidence interval: 0.84–1.64), and after further
restriction to patients who underwent therapeutic
cardiac procedures (n5 5660) it was 1.45 (95%
confidence interval: 0.86–2.29), based on 18
observed cancers. These 18 patients with cancer
had the following congenital heart defects: four
cases of ventricular septal defects, four cases of atrial
septal defects, three cases of coarctation of the aorta,
three cases of transposition of the great arteries, one
case of tetralogy of Fallot, one case of patent arterial
duct, one case of pulmonary valve stenosis, and one
case of malformation of the aortic valve.
Table 3 shows the standardised incidence ratios
of specific cancers with more than three observed
cancer cases in the overall cohort. The cancers were
all associated with congenital heart defects and
included 13 cases of brain tumours, 14 cases of
lymphoid leukaemia, nine cases of myeloid leukae-
mia, and four cases of basal cell carcinoma. The
brain tumours comprised four cases of benign
neoplasms – two of the pituitary gland – four
neoplasms of uncertain or unknown behaviour, and
five malignant neoplasms. After exclusion of patients
with Down’s syndrome, the standardised incidence
ratio was 1.43 (95% confidence interval: 0.57–2.94)
for lymphoid leukaemia and 2.53 (95% confidence
interval: 0.52–7.40) for myeloid leukaemia. We did
not find an increased incidence of thyroid cancer.
Discussion
To the best of our knowledge, this is the largest
study to examine the cancer risk in children and
young adults with congenital heart defects. We
found an increased risk of cancer for the overall
cohort, including patients with Down’s syndrome.
However, when Down’s syndrome patients were
excluded, our data did not support an association
between congenital heart defects and increased
cancer risk during the median follow-up of 8 years.
A few previous studies have focused on long-term
cancer risk in patients undergoing cardiac catheter-
isation. An Israeli study12 of 674 children under-
going catheterisation between 1950 and 1970 and a
mean follow-up time of 28.6 years reported a total
Table 1. Frequency of major congenital heart defect types in the
overall study population (15,905 patients).
Type of CHD Frequency, n (%)
Common arterial trunk 148 (0.9)
Transposition of great vessels 652 (4.1)
Tetralogy of Fallot 603 (3.8)
Ventricular septal defect 4153 (26.1)
Atrial septal defect 2520 (15.8)
Atrioventricular septal defect 726 (4.6)
Anomalies of heart valve 2412 (15.2)
Other specified anomalies of the heart 1121 (7.0)
Patent arterial duct 1850 (11.6)
Coarctation of the aorta 813 (5.1)
Other anomalies of the aorta 213 (1.3)
Stenosis or atresia of the pulmonary artery 564 (3.5)
Malformations of the great veins 130 (0.8)
15,905 (100)
CHD5 congenital heart defect
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of 11 cancers observed among male patients versus
4.75 expected (male-specific standardised incidence
ratio5 2.3, 95% confidence interval: 1.2–4.1). In
all, six of these cancers were diagnosed after 30 years
of follow-up from the first catheterisation. No
cancers were observed among female congenital
heart defect patients. The most frequent cancers
were lymphoma, in four male patients, and melanoma,
in three male patients. A larger Canadian study13 of
3915 children undergoing catheterisation between
1950 and 1965 and a median follow-up time of 21.7
years found an overall standardised incidence ratio of
0.75 (90% confidence interval: 0.44–1.20) on the
basis of 13 observed cancers; 10 of these cancers were
diagnosed 15 years after the first catheterisation. Of
the 13 cancers, there were three cases of leukaemia,
which was 1.6-fold (90% confidence interval:
0.43–4.14) the expected number.
Table 2. Standardised incidence ratios for cancer among patients with congenital heart defect, with and without exclusion of patients
with Down’s syndrome.
All CHD patients
(n5 15,905)
Patients with Down’s syndrome excluded*
(n5 15,104)
Observed
patients
with cancer
Expected
patients
with cancer
Standardised
incidence ratio
(95% CI)
Observed
patients
with cancer
Expected
patients
with cancer
Standardised
incidence ratio
(95% CI)
All patients 53 32.6 1.63 (1.22–2.13) 37 31.1 1.19 (0.84–1.64)
Sex
Men 23 17.1 1.34 (0.85–2.01) 19 16.3 1.16 (0.70–1.82)
Women 30 15.4 1.94 (1.31–2.77) 18 14.7 1.22 (0.72–1.93)
Follow-up (years)**
,1 10 2.9 3.44 (1.65–6.33) 3 2.8 1.09 (0.22–3.18)
1–5 17 8.9 1.91 (1.11–3.06) 10 8.4 1.19 (0.57–2.18)
.5 26 20.8 1.25 (0.82–1.83) 24 19.9 1.21 (0.77–1.79)
Year of CHD diagnosis
1978–1989 24 14.9 1.61 (1.03–2.39) 15 14.3 1.05 (0.59–1.74)
1990–1999 19 12.4 1.54 (0.93–2.40) 16 11.8 1.36 (0.78–2.20)
2000–2008 10 5.3 1.89 (0.91–3.48) 6 5.0 1.19 (0.44–2.59)
Patients undergoing therapeutic
cardiac procedures
22 13.3 1.65 (1.03–2.50) 18 12.4 1.45 (0.86–2.29)
Patients not undergoing
therapeutic cardiac procedures
31 19.2 1.61 (1.09–2.29) 19 18.7 1.02 (0.61–1.59)
CHD5 congenital heart defect
*Five patients with Fanconi anaemia were also excluded
**Years from diagnosis of congenital heart defect
Table 3. Standardised incidence ratios for specific cancers.
All CHD patients Patients with Down’s syndrome excluded*
Cancer site
Observed
patients
with
cancer
Expected
patients
with
cancer
Standardised
incidence ratio
(95% CI)
Observed
patients
with
cancer
Expected
patients
with
cancer
Standardised
incidence ratio
(95% CI)
All Brain 13 7.0 1.86 (0.99–3.17) 13 6.7 1.95 (1.04–3.33)
Lymphoid leukaemia 14 5.2 2.69 (1.47–4.52) 7 4.9 1.43 (0.57–2.94)
Myeloid leukaemia 9 1.2 7.22 (3.31–13.71) 3 1.2 2.53 (0.52–7.40)
Basal cell carcinoma 4 0.6 6.40 (1.74–16.39) 3 0.6 4.96 (1.02–14.49)
Only patients Brain 6 2.8 2.12 (0.78–4.62) 6 2.6 2.29 (0.84–5.00)
undergoing Lymphoid leukaemia 5 2.0 2.48 (0.80–5.77) 4 1.8 2.17 (0.59–5.56)
therapeutic Myeloid leukaemia 2 0.5 4.17 (0.50–15.06) 0 – –
cardiac
procedures
Basal cell carcinoma 3 0.3 10.70 (2.20–31.25) 2 0.3 7.48 (0.91–27.01)
CHD5 congenital heart defect
Only cancer sites with more than three cancers recorded, in the overall CHD cohort, are presented
*Five patients with Fanconi anaemia were also excluded
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Our results cannot be readily compared with
these studies’ results, as we did not have detailed
information on cardiac catheterisation. However, a
substantial proportion of the congenital heart defect
patients are known to have undergone either
therapeutic or diagnostic cardiac catheterisation in
our subcohorts who underwent cardiac therapeutic
interventions (Table 2).
Direct comparison is also hampered by the
incomplete follow-up and lack of data on Down’s
syndrome in both the Israeli and the Canadian
study. This may also have contributed to the
inconsistency between the results of the two studies.
The exclusion of patients with Down’s syndrome
from our study population attenuated the associa-
tion between congenital heart defect and cancer,
mainly owing to a decreased number of leukaemia
cases. This is in line with the previously reported
overall increased risk of leukaemia in patients with
Down’s syndrome7.
Organs around the heart are the most exposed to
radiation from cardiac catheterisation, and high
radiation doses have been measured in the lungs,
followed by bone surface, oesophagus, liver, and red
bone marrow – thoracic vertebra.20 In an explora-
tory analysis regarding specific cancer sites, there
was an association between congenital heart defects
and brain tumours (standardised incidence ratio:
1.95; 95% confidence interval: 1.04–3.33), as well
as congenital heart defects and basal cell carcinomas
(standardised incidence ratio: 4.96; 95% confidence
interval: 1.02–14.49) in our subcohort of congenital
heart defect patients without Down’s syndrome or
Fanconi anaemia. These cancer sites have been
associated with radiation,16,17 but on the other hand
we did not observe an increased risk of, for example,
thyroid cancer, which has also been associated with
radiation.21 Furthermore, the brain will receive very
little radiation during cardiac catheterisation.20 The
cancer risk associated with low-dose radiation
exposure has been estimated on the basis of a linear
extrapolation of high-dose data from, for example,
atomic bomb survivors, the so-called linear-no-
threshold model.11 However, according to Beels
et al,11 this model potentially underestimates the
risk associated with very low-dose radiation on
the basis of biomarker measurement indicating a
hypersensitivity to radiation at low doses.
We do not know whether radiation from cardiac
catheterisation played a role in the observed excess
risk of these specific cancers, given the reports of
DNA damage closely after cardiac catheterisation22
and the possible association between diagnostic
radiation and childhood cancer.10 In any respect,
the absolute number of excess cancers was small,
and the overall estimate in the cohort without
Down’s syndrome who underwent therapeutic
cardiac procedures was not statistically significant
(standardised incidence ratio: 1.45; 95% confidence
interval: 0.86–2.29). Leukaemia is the type of
cancer most strongly associated with radiation, with
a reported peak incidence in Russian nuclear
workers 3–5 years after initial radiation exposure.23
According to this, the median follow-up of 8 years
in the current study is judged sufficient to detect at
least some cases of radiation-linked leukaemia.
Strengths and limitations
The main strengths of this study include the use of
population-based data on congenital heart defect
and cancer, the virtually complete long-term follow-
up, the large sample size, and the ability to identify
patients with Down’s syndrome.
The main limitation of our study was the lack of
detailed data on radiation exposure from cardiac
catheterisations, which limited our ability to
examine a potential causal link between radiation
exposure during catheterisation and cancer devel-
opment. We were able to identify the patients with
procedure codes for invasive cardiac procedures in
the National Patient Registry, namely, heart surgery
or catheter-based therapeutic interventions. How-
ever, the procedure codes did not allow distinction
between the two treatment modalities. We would,
however, expect that all patients who underwent
surgery, in the time before the introduction of
echocardiography during the 1980s, also underwent
catheter-based examination. Later, and particularly
since the mid-1990s, an increasing proportion of
congenital heart defect patients underwent catheter-
based therapeutic interventions for, for example,
atrial septal defects and patent arterial duct. Since
the 1990s, we expect the patient radiation doses
during paediatric cardiac catheterisation to have
been comparable with that reported in the 1997
study by Boothroyd et al,24 from the United
Kingdom. We thus expect catheterised patients
during this period to have received a mean dose of
,30Gycm2 per procedure, varying substantially
from ,1Gycm2 up to 200Gycm2. Earlier, the
radiation doses were likely to be higher, owing to,
for example, less sophisticated equipment.25
We did not have information about computed
tomography scans either, but this imaging modality
was not part of the standard clinical work-up before
cardiac interventions for congenital heart disease.
We identified the congenital heart defect patients
using administrative databases, with a reported
positive predictive value regarding overall presence
of congenital heart defect of 89%.26 Although the
majority of misclassified congenital heart defect
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patients were excluded, based on extensive record
review and expert knowledge on the medical
doctors’ coding practices,14 some misclassification
of congenital heart defect status was probably
present. We therefore confirmed the congenital
heart defects of the 53 patients with cancer through
record review, and any inclusion of individuals
without congenital heart defect in the remaining
congenital heart defect cohort would most likely
render our estimates conservative.
The validity of the Cancer Registry data is
reported to be high19 and the registry is extensively
used for research purposes.27 The decreased number
of leukaemia patients observed after exclusion of
Down’s syndrome was expected7 and further
emphasise the validity of our data.
If congenital heart defect patients were diagnosed
with cancer at an earlier stage than the general
population, as a result of medical follow-up in
childhood, we would have overestimated the relative
risk of cancer in the congenital heart defect cohort in
the period shortly after diagnosis. However, in the
cohort without Down’s syndrome the risk of brain
tumours was increased more than 5 years after
congenital heart defect diagnosis (standardised inci-
dence ratio: 2.44; 95% confidence interval: 1.17–4.50)
compared with the general population, indicating that
this potential bias does not explain these results. Small
numbers did not allow analysis according to follow-up
time with regard to basal cell carcinomas, but two
were diagnosed after 1 year of follow-up and one after
5 years of follow-up.
We did not have information on social status, but
the population-based design combined with the
public Danish health-care system, with access free of
charge,28 limit the possibility of confounding from
social factors. The standardised estimates were
controlled for age, gender, and calendar time.
The follow-up of this cohort continues, and it
will thus be possible to study longer term cancer
risk in the years to come. At present, there are no
readily available nationwide databases on diagnostic
and therapeutic radiation exposure. However, a
nested case–control study, for example, based on
exposure information abstracted from medical
records of congenital heart disease patients with
and without cancer would be possible.
Conclusion
The overall cancer risk was not statistically
significantly elevated among congenital heart defect
patients without Down’s syndrome or Fanconi
anaemia when compared with the general popula-
tion. The risk of cancer was elevated in the overall
congenital heart defect population when compared
with the general population, but the absolute
number of cancers among congenital heart defect
patients up to 32 years of age was low. Studies with
longer follow-up and more information on radiation
doses are needed to further examine a potential
cancer risk associated with diagnostic radiation
exposure.
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